Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis.

Published in: The Annals of pharmacotherapy (2022)

Sutimlimab provides an additional therapeutic option in the treatment of CAD-associated hemolysis that can lead to rapid improvement in hemoglobin and anemia-related symptoms.

Keyphrases

red blood cell
coronary artery disease
sleep quality
iron deficiency
combination therapy
depressive symptoms
physical activity
quantum dots